Form 4: Astrana Health Director Matthew Mazdyasni Reports Acquisition and Disposal of Common Stock

Director Matthew Mazdyasni reports changes in beneficial ownership of Astrana Health, Inc. common stock, including the acquisition of restricted shares and adjustments to holdings.

Summary

• On August 13, 2024, Matthew Mazdyasni, a director of Astrana Health, Inc., reported transactions involving the company's common stock.
• Mazdyasni acquired 3,564 shares of restricted common stock under the Issuer's 2024 Equity Incentive Plan at a price of $0.
• These restricted shares will vest on the earlier of August 13, 2025, or the date of the Issuer's 2025 annual meeting of stockholders.
• Following the reported transactions, Mazdyasni beneficially owns 8,314 shares of common stock, including 4,750 shares of restricted stock vesting on December 9, 2024, and 3,564 shares vesting later.
• Mazdyasni has also granted a Power of Attorney to Brandon Sim, Chandan Basho, John Vong, and Kathy Diep to handle SEC filings on his behalf.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating routine transactions. The sentiment is neutral as it primarily reflects compliance with SEC regulations.

Positives

• The acquisition of restricted shares indicates confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Future Outlook

The vesting of restricted shares in the future suggests an expectation of continued service and contribution from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders, ensuring fair market practices.

Stakeholder Impact

• Shareholders are informed about insider transactions, promoting transparency.
• Employees may view the equity incentive plan as a positive aspect of their compensation.

Key Dates